Patents by Inventor Thierry Levade

Thierry Levade has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer
    Patent number: 11078277
    Abstract: The present invention relates to methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer. In particular, the present invention relates to a method of enhancing the CD8+ T cell-dependent immune response in a subject suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent capable of increasing intra-tumoral ceramide content.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: August 3, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Thierry Levade, Bruno Segui, Florie Bertrand, Julia Rochotte, Anne Montfort, Nathalie Andrieu-Abadie, Celine Colacios Viatge, Nicolas Meyer
  • Methods and pharmaceutical composition for the treatment of cancer
    Patent number: 10918737
    Abstract: The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNF? blocking agent to a subject in combination with the immune checkpoint inhibitor.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: February 16, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse III, Centre Hospitalier Universitaire de Toulouse
    Inventors: Thierry Levade, Bruno Segui, Nicolas Meyer, Céline Colacios Viatgé, Nathalie Andrieu-Abadie, Florie Bertrand
  • Methods for enhancing the potency of the immune checkpoint inhibitors
    Patent number: 10822415
    Abstract: The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: November 3, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE), Université Toulouse III—Paul Sabatier, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Thierry Levade, Nicolas Meyer, Céline Colacios Viatgé, Caroline Imbert, Nathalie Andrieu-Abadie, Bruno Segui
  • Method for treating melanoma
    Patent number: 10144772
    Abstract: The present invention relates to a TNF? blocking agent for use in the treatment and prevention of melanoma in a subject in whom melanoma cells express MHCI and in whom stroma cells exhibit TNF expression.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: December 4, 2018
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre Hospitalier Universitaire de Toulouse, Institut Claudius Regaud, Universite Paul Sabatier Toulouse III
    Inventors: Bruno Segui, Nathalie Andrieu-Abadie, Thierry Levade, Celine Colacios Viatge, Philippe Rochaix, Florie Bertrand, Herve Benoist, Julia Rochotte
  • Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination
    Patent number: 9851358
    Abstract: The present invention relates to methods and pharmaceutical compositions for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells). In particular, the present invention relates to a method for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells) in a subject suffering from a cancer comprising the steps consisting of i) determining the expression level of at least one biomarker selected from the group consisting of soluble CD95L and EMT promoting factors in a sample obtained from the subject, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering the subject with a therapeutically effective amount of C16-ceramide or derivatives such as C16-sphingomyelin and C16-glycosphingolipids when the expression level determined at step i) is higher than the predetermined reference value.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: December 26, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paul Sabatier Toulouse III, Centre Hospitalier Universitaire de Toulouse, Universite de Bourgogne, Universite de Rennes I, Universit des Antilles et de la Guiyane, Ecole des Hautes Etudes en Sante Publique (EHESP)
    Inventors: Patrick Legembre, Bruno Segui, Thierry Levade, Olivier Micheau
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR REDUCING METASTATIC DISSEMINATION
    Publication number: 20160327561
    Abstract: The present invention relates to methods and pharmaceutical compositions for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells). In particular, the present invention relates to a method for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells) in a subject suffering from a cancer comprising the steps consisting of i) determining the expression level of at least one biomarker selected from the group consisting of soluble CD95L and EMT promoting factors in a sample obtained from the subject, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering the subject with a therapeutically effective amount of C16-ceramide or derivatives such as C16-sphingomyelin and C16-glycosphingolipids when the expression level determined at step i) is higher than the predetermined reference value.
    Type: Application
    Filed: January 7, 2015
    Publication date: November 10, 2016
    Inventors: Patrick Legembre, Bruno Segui, Thierry Levade, Olivier Micheau